MUMBAI, India, June 30 -- Intellectual Property India has published a patent application (202541002589 A) filed by Manipal Academy Of Higher Education on January 11, 2025, for A Method And Composition For Targeted Inhalable Nanoparticles To Treat Lung Cancer.
Inventors include Usha Y Nayak; Akanksha D Dessai; and Sanjay Garg.
The application for the patent was published on June 26, 2026, under issue no. 26/2026.
Abstract: The present invention relates to an inhalable hybrid lipid-polymer nanoparticle (HLPN) formulation designed for the co-delivery of Nintedanib and Docetaxel to treat Non-Small Cell Lung Cancer (NSCLC). The invention overcomes the shortcomings of traditional therapies, including systemic toxicity, inadequate drug localization, and barriers posed by the tumor microenvironment, by offering a targeted delivery system. The approach enhances HLPN formulation with biocompatible substances such as TPGS, PLGA, and soy lecithin to obtain improved drug loading, stability, and effectiveness. Developed as a dry powder inhaler (DPI), the formulation administers medications straight to lung tissues, enhancing therapeutic results while reducing side effects. This method provides a budget-friendly, scalable, and patient- centric option that improves progression-free survival and overall survival in NSCLC therapy, aiding advancements in precision oncology and alleviating the burden of lung cancer. (FIG. 2)
Disclaimer: Curated by HT Syndication.
